Johnson & Johnson reported Phase‑3 trial results showing Tecvayli improved progression‑free survival and produced a survival signal in patients with earlier‑line multiple myeloma, data the company says supports expanding the drug’s use ahead of its prior, later‑line approvals. The MajesTEC‑9 study enrolled over 600 patients and compared Tecvayli against standard regimens in the first‑relapse setting. J&J said it will discuss the results with regulators and plans further presentations. The data bolster the company’s strategy to move a previously accelerated‑approval asset into earlier treatment lines and to build a broader myeloma franchise.